证券记录 · 已归档季度
NVO
Novo Nordisk A/S · Healthcare · Drug Manufacturers - General
17被追踪持有人
n/aΔ持有人
46.04M持有股份
$6.57B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 347.39K | $13.21M | n/a | −1 |
| Q2 2026 | 132 | 0 | 235.88M | $11.31B | +12 | −13 |
| Q1 2026 | 134 | -8 | 242.80M | $8.91B | +5 | −13 |
| Q4 2025 | 140 | +1 | 228.46M | $11.63B | +3 | −2 |
| Q3 2025 | 19 | -1 | 80.89M | $4.49B | +2 | −3 |
| Q2 2025 | 17 | -1 | 53.30M | $3.68B | +1 | −2 |
| Q1 2025 | 16 | 0 | 43.10M | $3.00B | n/a | n/a |
| Q4 2024 | 16 | -1 | 48.20M | $4.15B | +1 | −2 |
| Q3 2024 | 16 | -1 | 43.13M | $5.09B | +1 | −2 |
| Q2 2024 | 17 | n/a | 46.04M | $6.57B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fisher Asset Management ✦ | 13.37M | n/a | $1.91B | 0.8% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 9.50M | n/a | $1.36B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 9.17M | n/a | $1.31B | 2.2% | n/c | 1 | SEC ↗ |
| 4 | Capital World Investors ✦ | 4.46M | n/a | $637.59M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 2.17M | n/a | $309.12M | 0.3% | n/c | 1 | SEC ↗ |
| 6 | Markel Group ✦ | 2.15M | n/a | $306.89M | 3.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Tiger Global Management ✦ | 1.27M | n/a | $181.14M | 0.8% | n/c | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 960.85K | n/a | $137.15M | 0.5% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 873.11K | n/a | $124.63M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 759.38K | n/a | $108.39M | 0.2% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 691.44K | n/a | $98.70M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 12 | Arrowstreet Capital ✦ | 395.90K | n/a | $56.51M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 175.00K | n/a | $24.98M | 0.8% | n/c | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 46.70K | n/a | $6.67M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Coatue Management ✦ | 32.90K | n/a | $4.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 16 | AQR Capital Management ✦ | 17.16K | n/a | $2.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | Baillie Gifford ✦ | 44 | n/a | $6,281 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 1.21M 股份, $43.09M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据